Sobi Submits Application for Orfadin to EMA

News
Article

Sobi's application for Orfadin oral suspension has been validated by EMA.

Sobi announced that the company's application for Orfadin oral suspension has been validated by EMA. This new dosage form has been developed to facilitate the accuracy in administration of the desired Orfadin dose to pediatric patients and to increase expediency for the patients and their caregivers.
 
The oral suspension is included in a Paediatric Investigation Plan agreed with EMA in March 2012.

Source: Sobi

Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content